Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a siloxy group. The novel monofunctional polyethylene glycol (PEG) offers an alternative to methoxy polyethylene glycol.

Abstract: An oral rinse composition for alleviating xerostomia includes a polyethylene glycol derivative as an active ingredient, which allows not only covalent bonding of the composition to the oral mucosa without irritation to increase the oral moisturizing capacity, but also allows easy manufacture, storage, use and packaging by having a granule formulation.

Abstract: A uricase derivative co-conjugated with fatty acid-linked polyethylene glycol derivatives and optionally, alkoxy polyethylene glycol derivatives is presented. The uricase may be intramolecularly crosslinked. The uricase derivative of the present invention is intended for use as a treatment for gout or hyperuricemia.

Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a siloxy group. The novel monofunctional polyethylene glycol (PEG) offers an alternative to methoxy polyethylene glycol.

Abstract: The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for making such hemoglobin derivative. Various embodiments of the invention include crosslinked hemoglobin which is co-conjugated with both FA-PEG derivatives and alkoxy-PEG derivatives. Such hemoglobin derivative according to the invention exhibit non-toxicity and extended intravascular retention time.

Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a tertiary alkoxy group.

Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a tertiary alkoxy group.

Abstract: The present invention relates to a polyethylene glycol hydrogel injection, and, more particularly, to an injection to be administered into a joint (a synovial joint cavity) for the improvement of symptoms of arthritis by containing two separate buffer solutions, wherein a solution (1) contains a polyethylene glycol derivative with an electrophilic functional group and a buffer of pH 3.5 to 6, and a solution (2) contains a polyethylene glycol derivative with a nucleophilic functional group, hyaluronic acid, and a buffer of pH 7.5 to 11. The injection of the present invention is highly biocompatible and long-lasting in the joint, showing the efficacy of pain relief, cartilage protection, and inhibition of inflammation, thus offering the effective prevention and treatment of arthritis.

Abstract: Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease.

Abstract: The present invention provides a hair treatment composition comprising a multi-arm polyethylene glycol derivative (A) that contains two or more functional groups that may be covalently bound to amines, a hair treatment agent comprising the composition, and a method for using the same. Optionally, the composition may further comprise a polyethylene glycol derivative (B), a biocompatible polymer (C), or both, wherein the derivative (B) and polymer (C) each contains one or more functional groups that may react with the functional groups of the derivative (A).

Abstract: Novel N-2-methylmaleirnide pegylating reagents for the site specific pegylation of therapeutically active proteins and methods for such pegylation using said reagents.

Abstract: The present invention provides novel heterobifunctional and monobifunctional polyethylene glycol derivatives for the pegylation of therapeutically active proteins. The heterobifunctional PEGs which bear two different functional groups as well as the monobifunctional PEGs which contain two similar functional groups, may be used for cross-linking purposes. The cross-linking may be intramolecular between two areas within the same molecule or intermolecular between two separate molecules. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such bifunctional derivatives are described.

Abstract: The present invention provides novel monofunctional polyethylene glycol aldehydes for the pegylation of therapeutically active proteins. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such aldehydes are described.

Abstract: The present invention provides novel monofunctional polyethylene glycol aldehydes for the pegylation of therapeutically active proteins. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such aldehydes are described.

Abstract: The present invention relates to novel hexa-arm polyethylene glycol (6-arm PEG) and its derivatives. The core of 6-arm PEG derivatives is sorbitol and the end groups can be derivatized into many different reactive functionalities that are useful in conjugating with many different targets. The present invention also provides a biodegradable polymeric hydrogel-forming composition comprising the 6-arm PEG and its derivatives, and methods of using such 6-arm PEG derivatives as surgical or biological implants or sealants.

Abstract: The present invention relates to novel synthetic methods for PEG-maleimide derivatives, specifically, novel synthetic methods for PEG-maleimide. The final products thereof are useful as a pegylation reagent in the field of bioengineering and the medicinal field or the preparation of medical appliances and by conjugating with certain moieties or specific domains of polysaccharides and biological proteins such as antibodies as a bio-compatible or bio-degradable polymer.

Abstract: The present invention relates to novel synthetic methods for PEG-maleimide derivatives, specifically, novel synthetic methods for PEG-maleimide. The final products thereof are useful as a pegylation reagent in the field of bioengineering and the medicinal field or the preparation of medical appliances and by conjugating with certain moieties or specific domains of polysaccharides and biological proteins such as antibodies as a bio-compatible or bio-degradable polymer.

Abstract: The present invention provides novel monofunctional polyethylene glycol aldehydes for the pegylation of therapeutically active proteins. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such aldehydes are described.

Abstract: The present invention provides novel heterobifunctional and monobifunctional polyethylene glycol derivatives for the pegylation of therapeutically active proteins. The heterobifunctional PEGs which bear two different functional groups as well as the monobifunctional PEGs which contain two similar functional groups, may be used for cross-linking purposes. The cross-linking may be intramolecular between two areas within the same molecule or intermolecular between two separate molecules. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such bifunctional derivatives are described.

Abstract: The present invention provides novel monofunctional polyethylene glycol aldehydes for the pegylation of therapeutically active proteins. The pegylated protein conjugates that are produced, retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived. New syntheses for preparing such aldehydes are described.